Trials / Completed
CompletedNCT00254579
Study of CP-675,206 in Refractory Melanoma
A Phase 2, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 251 (actual)
- Sponsor
- AstraZeneca · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
CP-675,206 is a fully human monoclonal antibody (mAb). It binds to the CTLA4 molecule, which is expressed on the surface of activated T lymphocytes. CP-675,206 is thought to stimulate patients' immune systems to attack their tumors. CP-675,206 is not expected to have a direct effect on tumor cells. CP-675,206 been shown to induce durable tumor responses in patients with metastatic melanoma in Phase 1 and Phase 2 clinical studies.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CP-675,206 | 15 mg/kg Q12W dosing regimen |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2009-12-01
- Completion
- 2009-12-01
- First posted
- 2005-11-16
- Last updated
- 2012-06-07
Locations
65 sites across 9 countries: United States, Argentina, Australia, Canada, France, Germany, Italy, Spain, United Kingdom
Source: ClinicalTrials.gov record NCT00254579. Inclusion in this directory is not an endorsement.